Drug Trial Radar · NCT04176380
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Dec 2, 2020
Primary completion
Jan 30, 2023
Study completion Jun 6, 2023
Sponsor
- Lead sponsor
- Rapa Therapeutics LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Medical College of Wisconsin
- First posted
- Nov 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.
Conditions
- Relapsed, Refractory Multiple Myeloma
Interventions
RAPA-201 Autologous T cellsBiological
Autologous rapamycin resistant Th1/Tc1 cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rateTime frame: One (1) year after last dose of RAPA-201 cells.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.